Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Vitamin D and proteinuria: a critical review of molecular bases and clinical experience.

Pérez-Gómez MV, Ortiz-Arduán A, Lorenzo-Sellares V.

Nefrologia. 2013;33(5):716-26. doi: 10.3265/Nefrologia.pre2013.Apr.12025. Review. English, Spanish.

2.

Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy.

Sanchez-Niño MD, Bozic M, Córdoba-Lanús E, Valcheva P, Gracia O, Ibarz M, Fernandez E, Navarro-Gonzalez JF, Ortiz A, Valdivielso JM.

Am J Physiol Renal Physiol. 2012 Mar 15;302(6):F647-57. doi: 10.1152/ajprenal.00090.2011.

3.

Vitamin D, proteinuria, diabetic nephropathy, and progression of CKD.

Agarwal R.

Clin J Am Soc Nephrol. 2009 Sep;4(9):1523-8. doi: 10.2215/CJN.02010309. Review.

4.

Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease.

Bover J, Egido J, Fernández-Giráldez E, Praga M, Solozábal-Campos C, Torregrosa JV, Martínez-Castelao A.

Nefrologia. 2015;35(1):28-41. doi: 10.3265/Nefrologia.pre2014.Sep.11796. English, Spanish.

6.

Oral paricalcitol as antiproteinuric agent in chronic kidney disease.

de Lorenzo A, Salanova L, Bomback AS, Moya M, Coronel F, Bernis C, Sánchez-Tomero JA, Álvarez V.

Nefrologia. 2013;33(5):709-15. doi: 10.3265/Nefrologia.pre2013.Jun.11928.

7.

Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism.

Wang XX, Jiang T, Shen Y, Santamaria H, Solis N, Arbeeny C, Levi M.

Am J Physiol Renal Physiol. 2011 Mar;300(3):F801-10. doi: 10.1152/ajprenal.00338.2010.

8.

Suppression of renin-angiotensin gene expression in the kidney by paricalcitol.

Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, Li YC, Rodriguez-Iturbe B.

Kidney Int. 2008 Dec;74(11):1394-402. doi: 10.1038/ki.2008.408.

9.

Vitamin D down-regulates TRPC6 expression in podocyte injury and proteinuric glomerular disease.

Sonneveld R, Ferrè S, Hoenderop JG, Dijkman HB, Berden JH, Bindels RJ, Wetzels JF, van der Vlag J, Nijenhuis T.

Am J Pathol. 2013 Apr;182(4):1196-204. doi: 10.1016/j.ajpath.2012.12.011.

PMID:
23385000
10.

Therapeutic measures in proteinuric nephropathy.

Praga M.

Kidney Int Suppl. 2005 Dec;(99):S137-41. Review.

PMID:
16336567
11.

[Vitamin D and kidney diseases].

Cavalier É, Thervet É, Courbebaisse M.

Presse Med. 2013 Oct;42(10):1391-7. doi: 10.1016/j.lpm.2013.07.011. Review. French.

PMID:
24055557
12.

Vitamin D receptor activators upregulate and rescue podocalyxin expression in high glucose-treated human podocytes.

Verouti SN, Tsilibary EC, Fragopoulou E, Iatrou C, Demopoulos CA, Charonis AS, Charonis SA, Drossopoulou GI.

Nephron Exp Nephrol. 2012;122(1-2):36-50. doi: 10.1159/000346562.

PMID:
23548800
13.

The novel role of TRPC6 in vitamin D ameliorating podocyte injury in STZ-induced diabetic rats.

Zhang X, Song Z, Guo Y, Zhou M.

Mol Cell Biochem. 2015 Jan;399(1-2):155-65. doi: 10.1007/s11010-014-2242-9.

PMID:
25292315
14.
15.

Are vitamin D receptor agonists like angiotensin-converting enzyme inhibitors without side effects?

Agarwal R.

Kidney Int. 2010 Jun;77(11):943-5. doi: 10.1038/ki.2010.77.

16.

Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis.

Rubel D, Stock J, Ciner A, Hiller H, Girgert R, Müller GA, Gross O.

Nephrol Dial Transplant. 2014 May;29(5):1012-9. doi: 10.1093/ndt/gft434.

PMID:
24198271
17.

Vitamin D receptor activation: implications for daily practice.

Warnock DG.

Contrib Nephrol. 2011;171:172-80. doi: 10.1159/000327208. Review.

PMID:
21625108
18.

[Renin inhibition and the kidney].

Ecder T.

Turk Kardiyol Dern Ars. 2009 Oct;37 Suppl 7:28-31. Turkish.

19.

Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury.

He W, Kang YS, Dai C, Liu Y.

J Am Soc Nephrol. 2011 Jan;22(1):90-103. doi: 10.1681/ASN.2009121236.

20.

High level of proteinuria during treatment with renin-angiotensin inhibitors is a strong predictor of renal outcome in nondiabetic kidney disease.

Xie D, Hou FF, Fu BL, Zhang X, Liang M.

J Clin Pharmacol. 2011 Jul;51(7):1025-34. doi: 10.1177/0091270010377502.

PMID:
20978279

Supplemental Content

Support Center